February 19th 2024
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
February 12th 2024
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
February 5th 2024
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.
January 30th 2024
Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.
Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.
January 29th 2024
An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
January 23rd 2024
Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).
Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.
January 22nd 2024
A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.
The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.
January 16th 2024
Noopur Raje, MD discusses the rationale for utilizing BCMA-targeted CAR-T cell therapy in myeloma patients and uncover the similarities and differences when compared to BCMA bispecific.
Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.
January 15th 2024
Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.
Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
December 14th 2023
A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.